Vytrus Biotech S.A. Total Liabilities

Latest as of December 2025: €4.35 Million EUR ≈ $5.09 Million USD

Vytrus Biotech S.A. total liabilities. Based on the latest financial reports, Vytrus Biotech S.A. (VYT) has total liabilities worth €4.35 Million EUR (≈ $5.09 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Vytrus Biotech S.A.'s assets to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Vytrus Biotech S.A. (2020–2025)

Total liabilities of Vytrus Biotech S.A. from 2020 to 2025. This chart illustrates how Vytrus Biotech S.A.'s total liabilities have evolved over time, based on quarterly financial data.

Vytrus Biotech S.A. Competitors by Total Liabilities

The table below lists competitors of Vytrus Biotech S.A. ranked by their total liabilities.

Company Country Total Liabilities
Punjab Chemicals & Crop Protection Limited
NSE:PUNJABCHEM
India Rs2.93 Billion
JINSUNG T.E.C. Inc
KQ:036890
Korea ₩216.64 Billion
CVC Ltd
AU:CVC
Australia AU$258.96 Million
Stomil Sanok SA
WAR:SNK
Poland zł746.85 Million
Selvas Ai Inc.
KQ:108860
Korea ₩47.04 Billion
T.K.S. Technologies Public Company Limited
BK:TKS
Thailand ฿1.04 Billion
Zen Voce
TWO:3581
Taiwan NT$968.32 Million
Silver Pegasus Acquisition Corp.
NASDAQ:SPEG
USA $8.37 Million

Liability Composition Analysis (2020–2025)

This chart breaks down Vytrus Biotech S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Vytrus Biotech S.A..

Liquidity & Leverage Metrics

Vytrus Biotech S.A. Total Liabilities Ratios Explained

Vytrus Biotech S.A. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 3.03 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.42 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.30 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Vytrus Biotech S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Vytrus Biotech S.A. (2020–2025)

The table below shows the annual total liabilities of Vytrus Biotech S.A. from 2020 to 2025.

Year Total Liabilities Change
2025-12-31 €4.35 Million
≈ $5.09 Million
+13.44%
2024-12-31 €3.84 Million
≈ $4.49 Million
-4.57%
2023-12-31 €4.02 Million
≈ $4.70 Million
+23.76%
2022-12-31 €3.25 Million
≈ $3.80 Million
+10.85%
2021-12-31 €2.93 Million
≈ $3.43 Million
+12.83%
2020-12-31 €2.60 Million
≈ $3.04 Million
--

About Vytrus Biotech S.A.

MC:VYT Spain Biotechnology
Market Cap
$120.39 Million
€102.98 Million EUR
Market Cap Rank
#18250 Global
#124 in Spain
Share Price
€13.70
Change (1 day)
-2.49%
52-Week Range
€6.70 - €19.80
All Time High
€19.80
About

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Lon… Read more